晚发型重症肌无力具有独特的免疫学特征:一项探索性蛋白质组学研究
本研究利用BeatMG研究的基线血清样本,对21例早发型和28例晚发型重症肌无力患者进行768种炎症蛋白的探索性蛋白质组学分析,发现晚发型患者中白细胞分化与髓系白细胞分化迁移通路相关蛋白更丰富。在UK Biobank中7种蛋白有显著差异,并在独立验证队列中验证IL18R1、CXCL17和CCL11对晚发型重症肌无力具有特异性。
要点
- 晚发型重症肌无力患者血清中白细胞分化与迁移相关蛋白表达更丰富。
- IL18R1、CXCL17和CCL11在验证队列中被证实对晚发型重症肌无力具有特异性。
- 晚发型重症肌无力可能具有独特的免疫病理机制,这些蛋白有潜力作为生物标志物。
核心结论
- 晚发型重症肌无力具有独特的免疫病理机制,IL18R1、CXCL17和CCL11可能作为其特异性生物标志物。
研究设计与样本
- 探索性蛋白质组学研究,利用BeatMG研究基线血清样本分析768种炎症蛋白,并在UK Biobank和独立验证队列中进一步检验。
- 探索性分析纳入21例早发型(年龄38.3±12.1岁,16例女性[76.2%])和28例晚发型(年龄67.3±8.6岁,7例女性[25%])重症肌无力患者。
- 验证队列纳入80名参与者,包括39例重症肌无力患者(年龄54.33±18.9岁,17例女性[43.6%])和41名健康对照(年龄49.56±17.06岁,21例女性[66.1%])。
主要发现
- 晚发型重症肌无力组中参与白细胞分化调节、髓系白细胞分化与迁移通路的多种蛋白更为丰富。
- 从初始分析中选出的15种蛋白在UK Biobank队列中有7种存在显著差异。
- 在验证队列中,IL18R1、CXCL17和CCL11被验证对晚发型重症肌无力具有特异性。
临床怎么用
- IL18R1、CXCL17和CCL11等蛋白有望作为晚发型重症肌无力的生物标志物,辅助识别其独特免疫机制。
- 这些蛋白可能为晚发型重症肌无力提供更精准的治疗靶点,但需进一步前瞻性研究确认。
局限性
- 本研究为探索性分析,样本量有限,结论需进一步前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Approximately 80% of patients with myasthenia gravis (MG) have autoantibodies against acetylcholine receptor, and clinical characteristics may vary between early-onset (symptom onset age <50 years) and late-onset MG (EOMG and LOMG), but the pathophysiological differences between EOMG and LOMG are not well established. METHODS: We performed an exploratory in-depth proteomics analysis examining 768 inflammatory proteins utilizing the baseline serum samples from the BeatMG study (NCT02110706). We performed pathway enrichment analysis to assess the pathways involved in LOMG. A total of 15 selected proteins from the initial analysis were further examined using the UK Biobank and further quantified in a separate validation cohort. RESULTS: A total of 21 patients with EOMG (age 38.3 ± 12.1 years, 16 women [76.2%]) and 28 patients with LOMG (age 67.3 ± 8.6 years, 7 women [25%]) from the BeatMG study were included in the exploratory analysis. Several proteins involved in the regulation of leukocyte differentiation and myeloid leukocyte differentiation and migration pathways were more abundant in the LOMG group. Among them, 7 were significantly different in the UK Biobank cohort. A total of 80 participants (39 MG patients (age 54.33 ± 18.9 years, 17 women [43.6%]) and 41 healthy controls (age 49.56 ± 17.06 years, 21 women [66.1%]) were included in the validation cohort, and IL18R1, CXCL17, and CCL11 were validated to be specific for LOMG. INTERPRETATION: Growing evidence supports that LOMG has a distinct immune pathomechanism. Further prospective studies are warranted to confirm the utility of these proteins as biomarkers of LOMG, and the feasibility of using them for more precise therapeutic targets to improve patient outcomes. ANN NEUROL 2026;99:198-210.
引用
- Roy B, Chen J, Khani-Habibabadi F, et al. A Distinct Immunological Signature in Late-Onset Myasthenia Gravis: Insights from an Exploratory Proteomics Study. Ann Neurol. 2025. PMID: 40913424. doi:10.1002/ana.78017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。